What are synthetic drugs?
New, synthetic versions of harmful drugs, including synthetic opioids and synthetic cannabinoids, are increasingly found in UK’s illegal drug markets.

A general debate on the Covid-19 pandemic response and trends in excess deaths has been scheduled for 18 April in the Commons Chamber. The debate will be opened by Andrew Bridgen MP.
The debate will consider trends in excess deaths. Excess deaths are typically measured as the difference between the observed number of deaths within a period compared with the five-year average.
Mortality data published over the last four years shows a general increase in excess deaths. For the quarter ending September 2023, the number of deaths in England and Wales was 2.1% above the five-year average.
We can adjust this data to reflect demographic changes in the growing and ageing population – the age-standardised mortality rate (ASMR). The ASMR was 4.7% below the five-year average in the quarter ending September 2023, in England and Wales.
The government has acknowledged an increase in the number of excess deaths in England and Wales and has attributed these to a combination of factors, such as the prevalence of heart disease, flu and heart disease.
The Library briefing, Trends in excess deaths, provides further discussion.
The debate will also consider the Covid-19 pandemic response.
In May 2021, the then Prime Minister, Boris Johnson, announced that the UK Government would establish an independent public inquiry into the Covid-19 pandemic.
The terms of reference to the Inquiry set out that the Inquiry would examine, consider and report on preparations and the response to the pandemic in England, Wales, Scotland and Northern Ireland.
A separate Inquiry is taking place in Scotland, which will evaluate areas where policy is devolved to the Scottish Government.
The Inquiry was established under the Inquiries Act 2005. Inquiries held under this Act have the power to compel the production of documents and call witnesses to give evidence. Further information is available in the Library briefing, Statutory public inquiries: the Inquiries Act 2005.
In December 2021, the UK Government appointed the Rt Hon Baroness Heather Hallett DBE as Chair to the inquiry.
The Inquiry website provides information about the structure of the Inquiry, explaining that themes are grouped into modules focused on different aspects of the response to pandemic.
There is no set date for the Inquiry’s conclusion or final report, but public hearings are expected to continue until summer 2026. Baroness Hallett is expected to publish an initial report by summer 2024.
The debate will “call on the Covid-19 Inquiry to move onto its module four investigation into vaccines and therapeutics as soon as possible”.
Module four of the Inquiry, on vaccines and therapeutics, will consider and make recommendations on issues relating to the development of Covid-19 vaccines and the implementation of the rollout programme in England, Wales, Scotland and Northern Ireland. The module will also address issues relating to vaccine safety.
The Inquiry plans to hear evidence for this module in January 2025. Hearings for module four were initially scheduled to be held during summer 2024. These were subsequently delayed to enable organisations to prioritise evidence for module three on the pandemic’s impact on healthcare systems.
New, synthetic versions of harmful drugs, including synthetic opioids and synthetic cannabinoids, are increasingly found in UK’s illegal drug markets.
The Rare Cancers Bill 2024-2025 had its second reading on Friday 14 March 2025. It was considered in Public Bill Committee on 2 July 2025 and report stage is scheduled for 11 July 2025. This is a private members' bill.
This briefing focuses on two disease-modifying dementia drugs that are currently being appraised by the National Institute for Health and Care Excellence (NICE): lecanemab and donanemab